Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand

BACKGROUND: A prime-boost vaccination regimen with ALVAC-HIV (vCP1521) administered intramuscularly at 0, 4, 12, and 24 weeks and gp120 AIDSVAX B/E at 12 and 24 weeks demonstrated modest efficacy of 31.2% for prevention of HIV acquisition in HIV-uninfected adults participating in a community-based e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Bussaratid, Valai, Dhitavat, Jittima, Maekanantawat, Wirach, Pungpak, Swangjai, Suntharasamai, Pravan, Vanijanonta, Sirivan, Nitayapan, Sorachai, Kaewkungwal, Jaranit, Benenson, Michael, Morgan, Patricia, O'Connell, Robert J., Berenberg, Jeffrey, Gurunathan, Sanjay, Francis, Donald P., Paris, Robert, Chiu, Joseph, Stablein, Donald, Michael, Nelson L., Excler, Jean-Louis, Robb, Merlin L., Kim, Jerome H.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2011
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3244387/
https://ncbi.nlm.nih.gov/pubmed/22205930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0027837
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars